Humeral Shaft Fractures : Outcomes of Straight Percutaneous Intramedullary Nailing With Dynamic Distal Locking

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06999018

Enrollment

Registered

2025-05-31

Start date

2020-01-01

Completion date

2021-01-01

Last updated

2025-05-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronavirus Infections, COVID-19, Health Care Workers, Seroprevalence, Vaccination

Brief summary

This study looks at how many healthcare workers at CHSD have developed antibodies against COVID-19 after the second and third waves of the pandemic and following vaccination. By testing blood samples, we want to understand how well healthcare workers are protected, which work areas might be more at risk, and how immunity changes over time after infection or vaccination.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Inclusion criteria

* Patients operated between January 2008 and June 2018 * Closed, isolated, displaced fractures of the humeral shaft * Treatment by percutaneous anterograde intramedullary nailing with dynamic distal locking * Availability for follow-up and evaluation (e.g., Constant score assessment in June 2018)

Exclusion criteria

* Open fractures * Fractures that are not isolated or not displaced * Patients lost to follow-up at the June 2018 evaluation (18 excluded) * Lack of Constant score evaluation (patients not reviewed)

Design outcomes

Primary

Measure	Time frame
The seroprevalence of SARS-CoV-2 antibodies among healthcare workers at CHSD following COVID-19 vaccination and previous infection.	January 2008 - June 2018

Countries

France

Outcome results